Abstract
Background and aims
Budd Chiari syndrome (BCS) commonly affects adolescents and adults. With improved survival, important quality-of-life parameters such as sexual life and fertility become more relevant. This study was aimed to assess the gonadal function in male patients with BCS and the effect of treatment on gonadal function.
Methods
Thirty male patients with newly diagnosed BCS were prospectively assessed for the presence of gonadal dysfunction. Erectile function was assessed using standardized International Index of Erectile Function questionnaire (IIEF). Follicular stimulating hormone (FSH), luteinizing hormone (LH), sex hormone-binding globulin (SHBG), estradiol, total testosterone (TT), calculated free testosterone (cFT), calculated bioavailable testosterone (cBT), sperm count, and sperm motility were compared at baseline and at 6 months of treatment for the assessment of gonadal function.
Results
Sixteen (53.3%) out of 30 patients were sexually active at the time of study and 5/16 (31%) had erectile dysfunction. Hypogonadotropic hypogonadism (HH) was the most common pattern seen in 50% cases followed by hypergonadotropic hypogonadism (HyH) in 23% cases. 27% patients had eugonadism. At 6 months of treatment, 60% of patients in HH group became eugonadal as compared to only 14% in HyH group. Proportion of patients with erectile dysfunction reduced (5/16 vs 1/16) after 6 months of therapy. The improvement in sperm count and sperm motility was not significant.
Conclusion
Gonadal dysfunction is common in male patients with BCS. HH remains the most common type of hypogonadism BCS and the type which improves significantly after treatment.
Graphical abstract
Similar content being viewed by others
Data transparency
All data and materials as well as software application or custom code support their published claims and comply with field standards.
Data availability
Datasets generated and analyzed during the current study are available from the corresponding author on request.
Code availability (software application or custom code)
Not applicable.Not applicable.
Plant reproducibility
Current article does not contain any research related to plants; hence, this part is not applicable to current article.
Abbreviations
- LH:
-
Luteinizing hormone
- SHBG:
-
Sex hormone-binding globulin
- BCS:
-
Budd Chiari syndrome
- IIEF:
-
International index of erectile function
- FSH:
-
Follicular stimulating hormone
- cFT:
-
Calculated free testosterone
- cBT:
-
Calculated bioavailable testosterone
- CTP:
-
Child–Turcotte–Pugh
- MELD:
-
Model for end-stage liver disease
- HH:
-
Hypogonadotropic hypogonadism
- HyH:
-
Hypergonadotropic hypogonadism
References
Kharb S, Garg MK, Puri P, Brar KS, Pandit A, Srivastava S. Assessment of thyroid and gonadal function in liver diseases. Indian J Endocrinol Metab 2015;19(1):89–94
Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005;152(4):501–513
Gonzales PH, Rhoden CR, Luz C, Corrêa G, Barbosa-Coutinho LM, Oliveira MC. Male gonadal function, prolactin secretion and lactotroph population in an experimental model of cirrhosis. Braz J Med Biol Res 2007;40(10):1383–1388
Bandyopadhyay SK, Moulick A, Saha M, Dutta A, Bandyopadhyay R, Basu AK. A study on endocrine dysfunction in adult males with liver cirrhosis. J Indian Med Assoc 2009;107(12):866–869
Kim M, Kim SY, Rou WS, Hwang SW, Lee BS. Erectile dysfunction in patients with liver disease related to chronic hepatitis B. Clin Mol Hepatol 2015;21(4):352–357
Bannister P, Losowsky MS. Sex hormones and chronic liver disease. J Hepatol 1988;6(2):258–262
Serin A, Akarsu M, Akpinar H, Simsek I. Changes of some hormones levels in patients with Hepatitis b virus-related chronic liver disease. Gastroenterol Res 2013;6(4):134–138
Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004;350(6):578–585
Shukla A, Sadalage A, Gupta D, Gupte A, Mahapatra A, Mazumder D, et al. Pregnancy outcomes in women with Budd Chiari syndrome before onset of symptoms and after treatment. Liver Int 2018;38(4):754–759
Huyghe E, Kamar N, Wagner F, Capietto AH, El-Kahwaji L, Muscari F, et al. Erectile dysfunction in end-stage liver disease men. J Sex Med 2009;6(5):1395–1401
Burra P, Germani G, Masier A, et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 2010;89(12):1425–1429
Chien YC, Chiang HC, Lin PY, Chen YL. Erectile function in men with end-stage liver disease improves after living donor liver transplantation. BMC Urol 2015;15:83
Chiang HC, Chien YC, Lin PY, Lee HL, Chen YL. Assessing men with erectile dysfunction before and after living donor liver transplantation in real-world practice: Integrating laboratories into clinical settings. PLoS ONE 2018;13(11): e0206438
Shukla A, Bhatia SJ. Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. Indian J Gastroenterol 2010;29(1):8–11
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84(10):3666–3672
Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HWG, Behre HM, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010;16(3):231–245
Gariani K, Toso C, Philippe J, Orci LA. Effects of liver transplantation on endocrine function: a systematic review. Liver Int 2016;36(10):1401–1411
Chan MY, Chok KSH, Fung JYY, Ng SL, Yiu MK, Lo CM. Prospective study on sexual dysfunction in male Chinese liver transplant recipients. Am J Mens Health 2019;13(2):1557988319835139
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822–830
Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985;60(3):444–450
DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. Expert Rev Hematol 2014;7(6):767–773
Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93(7):988–993
Jones KM, Niaz MS, Brooks CM, Roberson SI, Aguinaga MP, Hills ER, et al. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Health 2009;6(3):1124–1144
Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Schölmerich J, et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol 2003;15(5):495–501
Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol 2015;30(2):244–251
Nitsche R, Coelho JC, Freitas AC, Zeni Neto C, Martins E. Testosterone changes in patients with liver cirrhosis before and after orthotopic liver transplantation and its correlation with MELD. Arq Gastroenterol 2014;51(1):59–63
Madersbacher S, Grünberger T, Maier U. Andrological status before and after liver transplantation. J Urol 1994;151(5):1251–1254
Griswold MD. Spermatogenesis: the commitment to meiosis. Physiol Rev 2016;96(1):1–17
Acknowledgements
The authors would like to thank Dr. Dinesh Uchil and Dr. Varsha Kale for their kind support at MRU Laboratory.
Funding
The study was funded by the Multidisciplinary Research Unit (MRU), Seth GSMC & KEM Hospital, Department of Health research, Govt. of India.
Author information
Authors and Affiliations
Contributions
Concept and design: AS and HD; consent and recruitment of participants: NR, VK, and AK; collection of blood samples and laboratory work: KK; data curation: NR and KK; data analysis and interpretation: NR, AK (Aditya Kale), SS, and AS; original manuscript: NR and KK; review and editing of manuscript: AS, SS, RS, TB, HD, and SP; supervision: SB, SS, and AS.
Corresponding author
Ethics declarations
Conflict of interest
Nitin Ramani, Kashmira Kawli, Abhijeet Karad, Aditya Kale, Vinit Kahalekar, Sridhar Sundaram, Shobna Bhatia, Ravikumar Shah, Tushar Bandgar, Hemant Deshmukh, Sujata Patwardhan, and Akash Shukla declare that we have no conflict of interest.
Consent to participate (include appropriate statements)
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.
Animal studies
This article does not contain any studies with animal subjects.
Ethical approval
Ethics committee approval was obtained. Letter reference no-EC/OA-55/2016.
Consent for publication (include appropriate statements)
The work has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis). The work is not under consideration elsewhere. Copyright has not been breached in seeking its publication. The publication has been approved by all co-authors and responsible authorities at the institute or organization where the work has been carried out.
Clinical trial registration
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ramani, N., Kawli, K., Karad, A. et al. Gonadal dysfunction in male patients with Budd Chiari syndrome and its reversibility with treatment. Hepatol Int 16, 640–648 (2022). https://doi.org/10.1007/s12072-022-10316-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-022-10316-9